drugset / Trial / NCT06935162
Teclistamab in Previously Treated AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Timeline
- Start
- 2025-05-21
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |